Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 10,853 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Cutaneous T-Cell Lymphoma (CTCL)
Interventions: SHAPE; Drug
Lead sponsor: TetraLogic Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Smoldering Multiple Myeloma
Interventions: IPH2101; Drug
Lead sponsor: Innate Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio + 2 more

Conditions: Herpes Zoster
Interventions: HZ/su, Flu D-QIV, mRNA-1273; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,013 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 46
States / cities: Tempe, Arizona • Oxnard, California • San Diego, California + 40 more

Conditions: Heart Failure
Interventions: Diuretics; Drug
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Columbus, Ohio • Oklahoma City, Oklahoma • Norfolk, Virginia

Conditions: Breast Cancer
Interventions: pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 3,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 539
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more

Conditions: Multiple Myeloma
Interventions: daratumumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 15
States / cities: Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 12 more

Conditions: Pneumococcal Disease
Interventions: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 1,997 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 105
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 78 more

Conditions: Ovarian Cancer, Sarcoma
Interventions: dolastatin 10; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 4
States / cities: Denver, Colorado • Rochester, Minnesota • Columbus, Ohio + 1 more

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 21
States / cities: New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more

Conditions: Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Localized Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Interventions: Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Vincristine Sulfate; Drug · Biological · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 196
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more

Conditions: Gastroesophageal Reflux
Interventions: Dexlansoprazole MR QD; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 52
States / cities: Hueytown, Alabama • Chandler, Arizona • Sierra Vista, Arizona + 49 more

Conditions: Heart Failure
Interventions: Attain Success Lead; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 2,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 72
States / cities: Little Rock, Arkansas • Downey, California • Modesto, California + 69 more

Conditions: Cardiac Arrest
Interventions: Therapeutic Hypothermia, Therapeutic Normothermia; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 48 Hours to 18 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-02341066, Pemetrexed, Docetaxel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 119
States / cities: Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 58 more

Conditions: Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
Interventions: Levosimendan, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more

Conditions: Postoperative Gastrointestinal Dysfunction
Interventions: TAK-954 Placebo, TAK-954; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 19
States / cities: Mobile, Alabama • Los Angeles, California • Orange, California + 14 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Conditions: Presbyopia
Interventions: Daily disposable multifocal soft contact lens; Device
Lead sponsor: Jennifer Fogt; Other
Eligibility: 38 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Columbus, Ohio • Granville, Ohio

Conditions: Cervical Spinal Cord Injury
Interventions: VX-210, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 14 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 33
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 30 more

Conditions: Malignant Thoracic Neoplasm
Interventions: Educational Activity, Electronic Health Record Review, Internet-Based Intervention, Media Intervention, Survey Administration; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Detrusor Hyperreflexia
Interventions: Oxybutynin; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 6 Years to 15 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 23
States / cities: Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more

Conditions: Lupus Arthritis
Interventions: Laquinimod, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Acute Myeloid Leukemia, Adult
Interventions: Revumenib, Placebo; Drug
Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland; Other
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Jacksonville, Florida + 11 more

Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1150
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more

Search by objective public record fields.

Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Attain Success Clinical Trial

Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of Soft Multifocal Lenses in Presbyopic Previous Contact Lens Wearers

Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])